Xenon Pharmaceuticals (XENE) Invested Capital: 2013-2025
Historic Invested Capital for Xenon Pharmaceuticals (XENE) over the last 11 years, with Sep 2025 value amounting to $559.5 million.
- Xenon Pharmaceuticals' Invested Capital fell 29.87% to $559.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $559.5 million, marking a year-over-year decrease of 29.87%. This contributed to the annual value of $754.9 million for FY2024, which is 18.65% down from last year.
- Latest data reveals that Xenon Pharmaceuticals reported Invested Capital of $559.5 million as of Q3 2025, which was down 11.75% from $634.0 million recorded in Q2 2025.
- Xenon Pharmaceuticals' Invested Capital's 5-year high stood at $927.9 million during Q4 2023, with a 5-year trough of $248.9 million in Q3 2021.
- Moreover, its 3-year median value for Invested Capital was $704.0 million (2025), whereas its average is $734.5 million.
- As far as peak fluctuations go, Xenon Pharmaceuticals' Invested Capital skyrocketed by 220.99% in 2021, and later fell by 29.87% in 2025.
- Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Invested Capital stood at $550.0 million in 2021, then spiked by 31.17% to $721.5 million in 2022, then grew by 28.61% to $927.9 million in 2023, then declined by 18.65% to $754.9 million in 2024, then decreased by 29.87% to $559.5 million in 2025.
- Its Invested Capital was $559.5 million in Q3 2025, compared to $634.0 million in Q2 2025 and $704.0 million in Q1 2025.